SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 UNDER
THE SECURITIES EXCHANGE ACT OF 1934
For the month of June 2017
Commission File Number 001-37846
CELLECT BIOTECHNOLOGY LTD.
(Translation of registrant’s name into English)
23 Hata’as Street
Kfar Saba, Israel 44425
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F x Form 40-F ¨
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(1): ¨
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(7): ¨
This Form 6-K is incorporated by reference into the Registrant’s Registration Statement on Form S-8 (Registration No. 333-214817).
Attached hereto as Exhibit 99.1 and incorporated by reference herein is a notice published by the Registrant entitled “Update on the Announcement on Moving to Exclusive Trading on the NASDAQ.”
Notice titled “Update on the Announcement on Moving to Exclusive Trading on the NASDAQ” published on June 26, 2017 (Unofficial Translation from Hebrew)
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|Cellect Biotechnology Ltd.|
|Date: June 26, 2017||By:||/s/ Eyal Leibovitz|
|Name: Eyal Leibovitz|
|Title: Chief Financial Officer|
Unofficial Translation into English from Hebrew
Cellect Biotechnology Ltd.
|Re:||Update on the Announcement on Moving to Exclusive Trading on the NASDAQ|
Cellect Biotechnology Ltd., No. 52-003648-4 (the “Company”) is pleased to announce that on September 5, 2017, the Company is moving to exclusive trading on the NASDAQ and that shareholders who are interested in continuing to hold/trade the Company shares on NASDAQ need to simply notify their bank or broker that holds their shares for them of their desire. The Company will bear the cost of the commissions associated with conversion of the shares for trading in the United States that the banks and brokers will charge for each person that converts their shares by July 31, 2017.
Shareholders of the Company are invited to contact the Company with any question by calling 09-974-1444.
|1.||The conversion of the shares for trading in the United States transfers the value of the shares from NIS to dollars.|
|2.||According to the Company’s estimation, no change or damage to the value of holdings or tradeability of ordinary shares is expected as a result of the conversion into ADSs or from the transfer of the value into dollars.|
|3.||The conversion takes place by ordinary shares in Israel converting into ADSs in the United States.|
|4.||One ADS is equal to 20 ordinary shares.|
|5.||The conversion into ADSs is purely technical.|
|6.||It will be possible to purchase and sell shares of the Company in exactly the same manner up till now through placing orders to purchase/sell to the banks or brokers that hold your shares on your behalf.|
The Company’s shares will shift to U.S. coverage and be removed from the Israeli stock exchange indexes at the semi-annual update of the composition of the indexes, that will go into effect at the close of trading on August 3, 2017.
The Company repeats and reminds you that the last date of trading of the Company’s shares on Tel Aviv will be September 3, 2017.
The Company urges all holders of ordinary shares that are traded on the Tel Aviv stock exchange to convert their shares at the earliest.
Cellect Biotechnology Ltd.